We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. GSK has a significant historical presence in Saudi Arabia having first started local commercial operations in 1950. GSK was the first multinational pharmaceutical company to have manufacturing facility in Saudi Arabia after establishing a joint venture with Banaja group in 1992 under the name of Glaxo Saudi Arabia Limited (GSAL). We develop and manufacture innovative products in the three primary areas of pharmaceuticals, vaccines and consumer healthcare. Since our first production in 1995, GSK has been increasing Its localization constantly in the last years, moving to 96 products currently manufactured in our factory in Jeddah. GSK launched 6 Innovative products in KSA in the last 5 years and also increased in 2017 its stake in GSAL to 75%. Through this investment, GSK reiterates its commitment to innovation and support the Government’s vision to increase local manufacturing of medical and healthcare products and foster local talent. Currently GSAL producing 80% of GSK’s pharma sales volume, with 1/3 being fully manufactured.

Visit Website: https://www.gsk.com/en-gb/

platinum SPONSORS


Arab Company for Pharmaceutical Products (Arabio) is the first company in the Gulf region that specialized in human vaccines and biological products. Arabio’s 11,000 m2 manufacturing site in Makkah is equipped with modern machines that match the requirements of Saudi Food and Drug Authority (SFDA), American Food and Drug Administration (US FDA), European Medicine Agency (EMA) and World Health Organization (WHO). Arabio represents one of the most important pillars of vaccines industry in Saudi Arabia and expanded to cover gulf countries while other markets are being evaluated in future expansion plan. Arabio is proud of its partnership with the global leader in human vaccines “Sanofi” to localize vaccine manufacturing technology in Saudi Arabia that will support the country vision, ensure a long-term impact on public-health and strengthen Arabio’s footprint in the region.

Visit Website: https://www.arabio.com/


Pharma Serve Co. Was established in June 1997. We are a subsidiary of Al Hammadi Holding Company. We represent Serum Institute of India, Sinovac Biotech co. and SK Bioscience. We won a contract from NUPCO to supply 20 Vaccines to MOH and other Government sectors. We have delivered over 18 million doses of different vaccine throughout the country. We demonstrated to NUPCO our ability to deliver all required vaccines in a timely manner. We deliver our products to all corners of Saudi Arabia by our fleet. we have a manufacturing strategy for vaccines that is in line with the Kingdom’s 2030 vision. We signed a manufacturing contract with our sister company Sudair Pharma to localize vaccine manufacturing. Pharma Serve Co. have become one of the top vaccine suppliers in Saudi Arabia.


We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Visit Website: https://www.sanofi.com/en



We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. At AstraZeneca, every day starts with the challenge of pushing the boundaries of science to deliver life changing medicine. Our inspiration is to improve 200 million patients across the world. AstraZeneca has been dedicated to providing a valuable contribution to patients’ care. Our success depends on a combination of scientific capabilities. We know the best science doesn’t happen through isolation, it happens through collaboration. When we go to work each day, we know that disease is complex and difficult to treat. But we believe that putting science at the center of everything we do is the best way to understand and transform disease to change people’s lives. In AstraZeneca, we aim at establishing the company as a leader in our focused therapy areas. In an effort to achieve our bold ambition, we are very keen to leverage the following main elements:

  • Improving patients’ lives through innovative medicines.
  • Implementing high quality Health Care Providers (HCPs) educational initiatives and rolling out valuable Key External Experts (KEEs) engagement projects.
  • Efficient collaboration with local societies to fight disease burden for better outcomes.
  • Building internal capabilities.
  • Ensure fair and motivational environment is dominating our culture.
  • Boosting compliance as the solid background for the entire work process.


At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

For more information, visit www.msd.com and connect with us on Facebook, Linkedin, Youtube, Instagram and Twitter at MSD GCC.


In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. 

Visit Website: https://www.tabukpharmaceuticals.com/

Visit Website: https://www.modernatx.com/



P: +971 4 361 9616  

M: +971 52 777 7498


© Copyright 2024 | 6th Annual Saudi International Vaccination Forum